Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human VIS171 SAD/MAD study in healthy volunteers and autoimmune disease participants
NL-OMON51485Phase 1Withdrawn
- Sponsor
- Parexel
- Start
- Sep 2022
- Modality
- Interleukins → Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of VIS171 in systemic lupus erythematosus (SLE), autoimmune hepatitis (AIH), focal segmental glomerulosclerosis (FSGS) and 2 more (3 arms), sponsored by Parexel. Primary endpoint: Incidence and severity of treatment-emergent adverse events. Planned start Sep 2022; status: withdrawn.
02
Drugs
VIS171
03
Conditions
systemic lupus erythematosus (SLE)autoimmune hepatitis (AIH)focal segmental glomerulosclerosis (FSGS)alopecia areataautoimmune disease
Beyond the preview
Go deeper on NL-OMON51485.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51485.